Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV001509080 | SCV001471251 | uncertain significance | not provided | 2022-04-28 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV001509080 | SCV001715601 | uncertain significance | not provided | 2022-02-15 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001509080 | SCV002953133 | likely benign | not provided | 2024-10-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004035525 | SCV003597557 | uncertain significance | not specified | 2022-01-05 | criteria provided, single submitter | clinical testing | The c.1124T>C (p.F375S) alteration is located in exon 9 (coding exon 9) of the SPTA1 gene. This alteration results from a T to C substitution at nucleotide position 1124, causing the phenylalanine (F) at amino acid position 375 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV001509080 | SCV003822611 | uncertain significance | not provided | 2023-12-22 | criteria provided, single submitter | clinical testing |